• Becton Dickinson recently saw the FDA revoke the Emergency Use Authorization for its BD Veritor rapid SARS-CoV-2 test at the company’s request, while the firm was also added to the Russell Midcap Index and Russell Midcap Value Index and removed from the Russell Top 200 Index and Russell Top 200 Value Index.
• Earlier in June, Vizient awarded BD’s CentroVena One Insertion System an Innovative Technology contract, signaling hospital decision-makers see its all-in-one central line solution as meaningfully improving safety and workflow.
• We’ll now examine how Vizient’s Innovative Technology contract for CentroVena One could influence Becton Dickinson’s medtech-focused investment narrative and outlook.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Becton Dickinson Investment Narrative Recap

To own Becton Dickinson, you need to believe its broad medtech portfolio and steady product innovation can offset near term margin pressures, recalls, and business separation risk. The FDA’s revocation of the BD Veritor SARS CoV 2 EUA, at BD’s request after transitioning to a cleared product, does not materially change the key near term catalysts or the biggest risks around execution, regulation, and trade.

The Vizient Innovative Technology contract for the CentroVena One Insertion System matters here because it reinforces BD’s push into higher value, differentiated medtech solutions. With hospital councils recognizing CentroVena One’s potential safety and workflow benefits, investors watching for innovation led growth and margin resilience may see this as an early proof point, even as regulatory scrutiny and product quality expectations remain elevated.

Yet while innovation wins headlines, the real risk investors should be aware of is...

Becton Dickinson's narrative projects $21.1 billion revenue and $1.8 billion earnings by 2029. This requires a 1.8% yearly revenue decline and roughly a $0.2 billion earnings increase from $1.6 billion today.

Uncover how Becton Dickinson's forecasts yield a $181.23 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were already assuming BD’s revenue could shrink about 3.5 percent a year and still reach about US$1.8 billion in earnings, so this new regulatory and product news may push those pessimistic views and the more balanced narrative even further apart.

Explore 3 other fair value estimates on Becton Dickinson - why the stock might be worth just $181.23!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Becton Dickinson research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.